Screener / SEC EDGAR /CIK 0001723128 /10-K filed Feb 27, 2026, compared with Feb 28, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Amneal Pharmaceuticals, Inc. AMRX

Compare with peers Embed
Planned sales, announced before they happen

1 trading plan running, 6 Form 144 notices for $11.0M

10-Q, 10-K and Form 144

What AMRX's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.

Plans adopted or ended

Trading plans · XBRL, 10-Q and 10-K

From Aug 15, 2024 to Dec 31, 2026. The thin line is today; a filled bar is a plan still running, a paler one has ended or expired.

InsiderWhatDateReported in
Deborah Autor
a director
Adopted 10b5-1 plan Sep 5, 2025 10-Q Nov 6, 2025
What the company wrote
On September 5, 2025, Deborah Autor, a director of the Company, adopted a trading plan intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. Ms. Autor’s plan provides for the sale of 34,819 shares of Class A common stock upon the vesting of restricted stock unit awards through December 31, 2026.
Gautam Patel
a director
Adopted 10b5-1 plan Aug 15, 2024 10-Q Nov 12, 2024
What the company wrote
On August 15, 2024, Gautam Patel, a director of the Company, adopted a 10b5-1 trading plan. Mr. Patel’s plan provides for the sale of 480,000 shares of Class A common stock of the Company through June 30, 2025.

From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 15 filings checked since May 9, 2023.

Notices of planned sales

Form 144 · Form 144 XML, SEC

What the sellers expected to sell on the Form 144 notices filed each month (the value on the notice).

FiledSellerSharesValue
Aug 13, 2026 JOHN KIELY
Director
50,000 $880K
Aug 12, 2026 NIKITA SHAH
Officer
146,403 $2.6M
Aug 12, 2026 JASON DALY
OFFICER
210,000 $3.6M
Aug 11, 2026 BUCHI J KEVIN
Director
168,573 $2.9M
May 11, 2026 DEBORAH AUTOR
DIRECTOR
34,819 $450K
Nov 17, 2025 Nark Ted C
Director
50,000 $591K

From the Form 144 XML filed with the SEC, since Nov 17, 2025. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.

Sources

Regulation S-K Item 408 in the XBRL of each 10-Q and 10-K (since 2023); the Form 144 XML at the SEC.

Also

Insider trades: the Form 4s for the sales these plans led to.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/AMRX/export.csv") into a cell.

Next:Owners
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.